Ceram Pharmaceuticals

About Ceram Pharmaceuticals

CytosinLab Therapeutics is a clinical-stage biotechnology firm established in 2019, concentrating on the field of epigenetics to develop new cancer therapies. The company was co-founded by a team with deep expertise in the field, including CEO Dr. Wu Haiping, who has over a decade of experience at Novartis leading therapies into clinical trials; COO Dr. Mi Yuan, with more than 20 years in the biopharmaceutical industry; and Academician Xu Guoliang, a distinguished figure in China's modern epigenetic research. The founding team's extensive background in both academic research and pharmaceutical development forms the company's scientific foundation.

The company's core business revolves around translating advanced epigenetic research into clinical applications for treating a wide array of hematologic malignancies and solid tumors. Its business model combines a proprietary research platform with the development of a pipeline of therapeutic assets. Revenue generation is anticipated through the successful clinical development and commercialization of its drug candidates, as well as potential partnerships and collaborations within the pharmaceutical industry. CytosinLab operates from its headquarters in Hangzhou and an R&D center in Shanghai, China.

At the heart of its operations is the EpigenPLUS platform, an internally developed system designed to efficiently assess and convert novel epigenetic mechanisms and targets into innovative drugs and diagnostics. This platform underpins the company's entire drug discovery process. CytosinLab has built a diverse pipeline of drug candidates, with several first-in-class small-molecule projects advancing to clinical trials. One of its key candidates, CTS2190, is an oral inhibitor of PRMT1 that has shown a favorable safety profile and notable anti-tumor activity in Phase I trials for patients with advanced solid tumors. The company is also exploring the application of epigenetics in other areas such as neurodegenerative diseases and regenerative medicine.

Since its inception, CytosinLab has secured significant funding to advance its research and clinical programs. A Series A financing round in January 2022 raised nearly CNY 200 million, led by investors including Lake Capital and CDH Capital. This was followed by a Series A+ round in late 2023, which brought in nearly CNY 100 million from investors such as Fortune Capital and Heda Industrial Fund Investment. The company has also been selected as a member of the Roche Accelerator, enabling collaborations on early-stage research projects.